Summary

Market Overview
The Global Targeted Cancer Therapy Market was valued at USD 16.55 Billion in 2024 and is projected to reach USD 25.24 Billion by 2030, growing at a CAGR of 7.25%. This market forms a crucial segment of the broader oncology landscape, emphasizing precision treatment approaches that act on specific genetic mutations, proteins, or cellular environments contributing to cancer progression. Targeted therapies aim to maximize treatment efficacy while minimizing collateral damage often seen with traditional chemotherapy and radiation. The industry includes an array of modalities such as monoclonal antibodies, kinase inhibitors, immune checkpoint inhibitors, and small molecules. Continued innovation, R&D investment, and active clinical trial pipelines are accelerating product development, thereby fostering improved patient outcomes and expanding therapeutic possibilities across various cancer types.
Key Market Drivers
Increasing Prevalence of Various Type of Cancers
Rising cancer prevalence globally is a major force fueling the demand for targeted cancer therapies. As of 2020, cancer accounted for nearly 10 million deaths annually, making it a dominant health and economic concern. Pediatric cancer remains a high-priority area, with roughly 400,000 new diagnoses each year. Patterns of incidence vary by geography, with cervical cancer topping the list in 23 countries, reflecting inequalities in HPV vaccination and screening. This variation signals untapped markets for tailored diagnostics and therapies. Lung cancer, representing about 12.4% of all new cancer cases, remains the deadliest, contributing to 18.7% of all cancer-related fatalities. As aging populations, lifestyle shifts, and environmental exposures drive global cancer rates upward, targeted therapies provide more effective, less toxic alternatives to conventional treatments. Their ability to deliver personalized, gene-specific interventions positions them as essential tools in modern oncology, especially in light of these growing epidemiological trends.
Key Market Challenges
High Cost and Side Effects Associated with the Targeted Therapies
The considerable cost of targeted cancer treatments presents a substantial hurdle to widespread adoption. Advanced therapies such as monoclonal antibodies and gene modulators demand high manufacturing investment and specialized administration, resulting in elevated prices for patients and healthcare systems. According to the American Association for Cancer Research, the U.S. could see national cancer-related costs exceed USD 245 billion by 2030—an increase of over 30% since 2015. Patients undergoing initial, ongoing, or end-of-life cancer care can incur average annual costs ranging from USD 5,300 to over USD 41,800. This economic burden affects access to care and can lead to financial distress for both patients and healthcare providers. Additionally, while targeted therapies are generally safer than traditional chemotherapy, they are not devoid of side effects, including immune-related adverse events or organ toxicity. These challenges call for innovative cost-control strategies, reimbursement policy revisions, and research into affordable alternatives to sustain market growth.
Key Market Trends
Advancements In Genomic Profiling and Precision Medicine
The integration of genomic profiling and precision medicine is transforming cancer treatment, driving greater adoption of targeted therapies. Next-generation sequencing (NGS) and liquid biopsy technologies now enable precise identification of genetic mutations that drive cancer, allowing clinicians to tailor treatment plans based on each patient’s unique tumor profile. These innovations have led to more effective, personalized therapies with fewer adverse effects. Precision medicine is also becoming instrumental in tracking disease progression and resistance patterns, enabling real-time adjustments to treatment. As these tools become more accessible, healthcare systems worldwide are increasingly implementing genomic-based protocols. This evolution in oncology practice underscores the growing reliance on targeted treatments and supports their rising use as a mainstay in cancer care strategies.
Key Market Players
• Amgen Inc.
• AstraZeneca plc
• Bayer AG
• Bristol-Myers Squibb Company
• F. Hoffmann-La Roche Ltd
• GlaxoSmithKline plc
• Johnson & Johnson Service Inc.
• Merck & Co. Inc.
• Novartis AG
• Pfizer Inc.
Report Scope:
In this report, the Global Targeted Cancer Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
• Targeted Cancer Therapy Market, By Therapy Type:
o Hormone Therapies
o Monoclonal Antibodies
o Signal Transduction Inhibitors
o Gene Expression Modulators
o Apoptosis Inhibitors
o Others
• Targeted Cancer Therapy Market, By Disease Indication:
o Lung Cancer
o Breast Cancer
o Colorectal Cancer
o Leukemia
o Melanoma
o Lymphoma
o Others
• Targeted Cancer Therapy Market, By End User:
o Hospitals & Clinics
o Cancer & Radiation Therapy Centers
o Academic & Research Institutions
• Targeted Cancer Therapy Market, By Region:
o North America
§ United States
§ Canada
§ Mexico
o Europe
§ France
§ United Kingdom
§ Italy
§ Germany
§ Spain
o Asia-Pacific
§ China
§ India
§ Japan
§ Australia
§ South Korea
o South America
§ Brazil
§ Argentina
§ Colombia
o Middle East & Africa
§ South Africa
§ Saudi Arabia
§ UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Targeted Cancer Therapy Market.
Available Customizations:
Global Targeted Cancer Therapy market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
• Detailed analysis and profiling of additional market players (up to five).

ページTOPに戻る

Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Targeted Cancer Therapy Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Therapy Type (Hormone Therapies, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors, Others)
5.2.2. By Disease Indication (Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Melanoma, Lymphoma, Others)
5.2.3. By End User (Hospitals & Clinics, Cancer & Radiation Therapy Centers, Academic & Research Institutions)
5.2.4. By Region
5.2.5. By Company (2024)
5.3. Market Map
6. North America Targeted Cancer Therapy Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Therapy Type
6.2.2. By Disease Indication
6.2.3. By End User
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Targeted Cancer Therapy Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Therapy Type
6.3.1.2.2. By Disease Indication
6.3.1.2.3. By End User
6.3.2. Canada Targeted Cancer Therapy Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Therapy Type
6.3.2.2.2. By Disease Indication
6.3.2.2.3. By End User
6.3.3. Mexico Targeted Cancer Therapy Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Therapy Type
6.3.3.2.2. By Disease Indication
6.3.3.2.3. By End User
7. Europe Targeted Cancer Therapy Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Therapy Type
7.2.2. By Disease Indication
7.2.3. By End User
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Targeted Cancer Therapy Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Therapy Type
7.3.1.2.2. By Disease Indication
7.3.1.2.3. By End User
7.3.2. United Kingdom Targeted Cancer Therapy Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Therapy Type
7.3.2.2.2. By Disease Indication
7.3.2.2.3. By End User
7.3.3. Italy Targeted Cancer Therapy Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Therapy Type
7.3.3.2.2. By Disease Indication
7.3.3.2.3. By End User
7.3.4. France Targeted Cancer Therapy Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Therapy Type
7.3.4.2.2. By Disease Indication
7.3.4.2.3. By End User
7.3.5. Spain Targeted Cancer Therapy Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Therapy Type
7.3.5.2.2. By Disease Indication
7.3.5.2.3. By End User
8. Asia-Pacific Targeted Cancer Therapy Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Therapy Type
8.2.2. By Disease Indication
8.2.3. By End User
8.2.4. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Targeted Cancer Therapy Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Therapy Type
8.3.1.2.2. By Disease Indication
8.3.1.2.3. By End User
8.3.2. India Targeted Cancer Therapy Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Therapy Type
8.3.2.2.2. By Disease Indication
8.3.2.2.3. By End User
8.3.3. Japan Targeted Cancer Therapy Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Therapy Type
8.3.3.2.2. By Disease Indication
8.3.3.2.3. By End User
8.3.4. South Korea Targeted Cancer Therapy Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Therapy Type
8.3.4.2.2. By Disease Indication
8.3.4.2.3. By End User
8.3.5. Australia Targeted Cancer Therapy Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Therapy Type
8.3.5.2.2. By Disease Indication
8.3.5.2.3. By End User
9. South America Targeted Cancer Therapy Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Therapy Type
9.2.2. By Disease Indication
9.2.3. By End User
9.2.4. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Targeted Cancer Therapy Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Therapy Type
9.3.1.2.2. By Disease Indication
9.3.1.2.3. By End User
9.3.2. Argentina Targeted Cancer Therapy Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Therapy Type
9.3.2.2.2. By Disease Indication
9.3.2.2.3. By End User
9.3.3. Colombia Targeted Cancer Therapy Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Therapy Type
9.3.3.2.2. By Disease Indication
9.3.3.2.3. By End User
10. Middle East and Africa Targeted Cancer Therapy Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Therapy Type
10.2.2. By Disease Indication
10.2.3. By End User
10.2.4. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Targeted Cancer Therapy Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Therapy Type
10.3.1.2.2. By Disease Indication
10.3.1.2.3. By End User
10.3.2. Saudi Arabia Targeted Cancer Therapy Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Therapy Type
10.3.2.2.2. By Disease Indication
10.3.2.2.3. By End User
10.3.3. UAE Targeted Cancer Therapy Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Therapy Type
10.3.3.2.2. By Disease Indication
10.3.3.2.3. By End User
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions
13. Global Targeted Cancer Therapy Market: SWOT Analysis
14. Competitive Landscape
14.1. Amgen Inc.
14.1.1. Business Overview
14.1.2. Product & Service Offerings
14.1.3. Recent Developments
14.1.4. Financials (If Listed)
14.1.5. Key Personnel
14.1.6. SWOT Analysis
14.2. AstraZeneca plc
14.3. Bayer AG
14.4. Bristol-Myers Squibb Company
14.5. F. Hoffmann-La Roche Ltd
14.6. GlaxoSmithKline plc
14.7. Johnson & Johnson Service Inc.
14.8. Merck & Co. Inc.
14.9. Novartis AG
14.10.Pfizer Inc.
15. Strategic Recommendations
16. About Us & Disclaimer